Metformin Prevents Liver Tumorigenesis by Inhibiting Pathways Driving Hepatic Lipogenesis

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Cancer Prevention Research

• Publication date

  2012-03-31

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1940-6207.CAPR-11-0228PMID 22467080PMCID PMC3324649
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Metformin and cancer: new applications for an old drug

  2012cited by this paper
• Global cancer statistics

  2011cited by this paper
• Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state.

  2010cited by this paper
• Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase.

  2010cited by this paper
• Metformin Prevents Tobacco Carcinogen–Induced Lung Tumorigenesis

  2010cited by this paper
• Insulin‐independent promotion of chemically induced hepatocellular tumor development in genetically diabetic mice

  2010cited by this paper
• Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis

  2010cited by this paper
• Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease

  2010cited by this paper
• Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression.

  2010cited by this paper
• Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner.

  2010cited by this paper
• Metformin suppresses azoxymethane‐induced colorectal aberrant crypt foci by activating AMP‐activated protein kinase

  2010cited by this paper
• Sterol metabolism and SREBP activation.

  2010cited by this paper
• Abrogation of hepatic ATP‐citrate lyase protects against fatty liver and ameliorates hyperglycemia in leptin receptor‐deficient mice

  2009cited by this paper
• Liver X receptor mediates hepatitis B virus X protein–induced lipogenesis in hepatitis B virus–associated hepatocellular carcinoma

  2009cited by this paper
• Hepatitis C Virus Proteins Induce Lipogenesis and Defective Triglyceride Secretion in Transgenic Mice*

  2009cited by this paper
• Antidiabetic therapy and increased risk of hepatocellular carcinoma in chronic liver disease.

  2009cited by this paper
• LKB1 and mammalian target of rapamycin as predictive factors for the anticancer efficacy of metformin.

  2009cited by this paper
• Diet‐induced hepatocellular carcinoma in genetically‐predisposed mice

  2009cited by this paper
• The impact of obesity and diabetes mellitus on the risk of hepatocellular carcinoma.

  2009cited by this paper
• The role of the lipogenic pathway in the development of hepatic steatosis.

  2008cited by this paper
• SREBP Activity Is Regulated by mTORC1 and Contributes to Akt-Dependent Cell Growth

  2008cited by this paper
• The Effects of Adiponectin and Metformin on Prostate and Colon Neoplasia Involve Activation of AMP-Activated Protein Kinase

  2008cited by this paper
• Metformin suppresses intestinal polyp growth in ApcMin/+ mice

  2008cited by this paper
• Fatty acid synthase gene is up-regulated by hypoxia via activation of Akt and sterol regulatory element binding protein-1.

  2008cited by this paper
• The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level

  2008cited by this paper
• Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth.

  2008cited by this paper
• Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan.

  2008cited by this paper
• Brick by brick: metabolism and tumor cell growth.

  2008cited by this paper
• Hepatitis B virus X protein induces lipogenic transcription factor SREBP1 and fatty acid synthase through the activation of nuclear receptor LXRalpha.

  2008cited by this paper
• Hepatocellular carcinoma: epidemiology and molecular carcinogenesis.

  2007cited by this paper
• Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells.

  2007cited by this paper
• Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis

  2007cited by this paper
• Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells.

  2006cited by this paper
• 5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside and metformin inhibit hepatic glucose phosphorylation by an AMP-activated protein kinase-independent effect on glucokinase translocation.

  2006cited by this paper
• ATP citrate lyase inhibition can suppress tumor cell growth.

  2005cited by this paper
• Hic-5 regulates an epithelial program mediated by PPARgamma.

  2005cited by this paper
• Global Cancer Statistics, 2002

  2005cited by this paper
• cDNA microarray analysis of HBV transgenic mouse liver identifies genes in lipid biosynthetic and growth control pathways affected by HBV

  2005cited by this paper
• ATP citrate lyase is an important component of cell growth and transformation

  2005cited by this paper
• Co-ordinate activation of lipogenic enzymes in hepatocellular carcinoma.

  2005cited by this paper
• The Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin

  2005cited by this paper
• Hepatocellular carcinoma: recent trends in the United States.

  2004cited by this paper
• Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study.

  2004cited by this paper
• Metformin in non-alcoholic steatohepatitis.

  2002cited by this paper
• Role of AMP-activated protein kinase in mechanism of metformin action.

  2001cited by this paper
• Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States

  2001influential reference
• Metformin in non-alcoholic steatohepatitis.

  2001cited by this paper
• Hepatic hyperplasia in noncirrhotic fatty livers: is obesity-related hepatic steatosis a premalignant condition?

  2001cited by this paper
• The role of diabetes in hepatocellular carcinoma: a case-control study among United States veterans

  2001cited by this paper
• Mechanism by which metformin reduces glucose production in type 2 diabetes.

  2000cited by this paper
• The antihyperglycaemic effect of metformin: therapeutic and cellular mechanisms.

  1999cited by this paper
• Cannabis use in relation to illicit drug use and health problems among opiate misusers in treatment

  1999cited by this paper

• AMPK activation prevents hepatocellular carcinoma development through inhibition of HNF4α activity

  2025cites this paper
• The Role of Metformin in cancer Prevention and Treatment: A Game Changer?

  2025cites this paper
• The multifaceted role of agents counteracting metabolic syndrome: A new hope for gastrointestinal cancer therapy.

  2025cites this paper
• Modulatory effect of metformin and its transporters on immune infiltration in tumor microenvironment: a bioinformatic study with experimental validation

  2025cites this paper
• Drug Repurposing: A Conduit to Unravelling Metabolic Reprogramming for Cancer Treatment.

  2025cites this paper
• Metformin upregulates circadian gene PER2 to inhibit growth and enhance the sensitivity of glioblastoma cell lines to radiotherapy via SIRT2/G6PD pathway

  2025cites this paper
• Crosstalk between Epigenetics and Metabolic Reprogramming in Metabolic Dysfunction-Associated Steatotic Liver Disease-Induced Hepatocellular Carcinoma: A New Sight

  2024cites this paper
• Antitumor Activity of Metformin Combined with Locoregional Therapy for Liver Cancer: Evidence and Future Directions

  2023cites this paper
• Immunometabolic factors contributing to obesity-linked hepatocellular carcinoma

  2023cites this paper
• Co‐drug development of gallic acid and metformin targeting the pro‐inflammatory cytokines for the treatment of breast cancer

  2023cites this paper
• A pilot metabolomic study of drug interaction with the immune response to seasonal influenza vaccination

  2023cites this paper
• Metformin Induces Lipogenesis and Apoptosis in H4IIE Hepatocellular Carcinoma Cells

  2023cites this paper
• Diabetes medications and cancer risk associations: a systematic review and meta-analysis of evidence over the past 10 years

  2023cites this paper
• Characterization of stem cell subtypes and prognostic signature in hepatocellular carcinoma

  2023cites this paper
• Regulation and targeting of SREBP-1 in hepatocellular carcinoma

  2023cites this paper
• Estrogen Attenuates Diethylnitrosamine-Induced Hepatocellular Carcinoma in Female Rats via Modulation of Estrogen Receptor/FASN/CD36/IL-6 Axis.

  2023cites this paper
• Re-evaluation of the anticarcinogenic effect of metformin in a chemically-induced hepatocellular carcinoma model not associated with diabetes

  2022cites this paper
• Efficacy of metformin on protein profile in breast tumor cells by assessment in vitro and in silico analysis In vitro ve in silico analizi ile metforminin meme tümörü hücrelerinde protein

  2022cites this paper
• TMEM88 Modulates Lipid Synthesis and Metabolism Cytokine by Regulating Wnt/β-Catenin Signaling Pathway in Non-Alcoholic Fatty Liver Disease

  2022cites this paper
• Role of metformin in the diagnosis, prevention, and treatment of hepatocellular carcinoma.

  2022cites this paper
• Metabolic dysfunction and cancer in HCV: shared pathways and mutual interactions.

  2022cites this paper
• Recent Insights of Metformin on Hepatocellular Carcinoma (HCC).

  2022cites this paper
• Metformin Modulates T Cell Function and Alleviates Liver Injury Through Bioenergetic Regulation in Viral Hepatitis

  2021cites this paper
• Risk Factors and Prevention of Viral Hepatitis-Related Hepatocellular Carcinoma

  2021cites this paper
• NAFLD: Diagnostic Algorithms for Regulating Patient Fluxes.

  2021cites this paper
• The Role of the PRMT5–SND1 Axis in Hepatocellular Carcinoma

  2021cites this paper
• Plasma lipids, tumor parameters and survival in HCC patients with HBV and HCV

  2020cites this paper
• NCOA5 deficiency promotes a unique liver protumorigenic microenvironment through p21WAF1/CIP1 overexpression, which is reversed by metformin

  2020cites this paper
• Molecular Mechanisms Regulating Obesity-Associated Hepatocellular Carcinoma

  2020cites this paper
• Theaphenon E prevents fatty liver disease and increases CD4+ T cell survival in mice fed a high-fat diet.

  2020cites this paper
• Metformin: A Possible Option in Cancer Chemotherapy

  2020cites this paper
• IS METFORMIN A GEROPROTECTOR? A PEEK INTO THE CURRENT CLINICAL AND EXPERIMENTAL DATA.

  2020cites this paper
• Metformin: Metabolic Rewiring Faces Tumor Heterogeneity

  2020cites this paper
• Combination therapy with metformin and IL-12 to inhibit the growth of hepatic carcinoma by promoting apoptosis and autophagy in HepG2-bearing mice.

  2020cites this paper
• The vital role of ATP citrate lyase in chronic diseases

  2019cites this paper
• Marqueurs diagnostiques et pronostiques de la stéatohépatite métabolique

  2019cites this paper
• A Network-based Analysis of Hepatocellular Carcinoma

  2019cites this paper
• Recommendations for Management and Treatment of Nonalcoholic Steatohepatitis

  2019cites this paper
• Of mice and men: Is there a future for metformin in the treatment of hepatic steatosis?

  2019cites this paper
• Metformin delays AKT/c‐Met‐driven hepatocarcinogenesis by regulating signaling pathways for de novo lipogenesis and ATP generation

  2019cites this paper
• Metformin Counteracts HCC Progression and Metastasis Enhancing KLF6/p21 Expression and Downregulating the IGF Axis

  2019cites this paper
• The Role of AMP-Activated Protein Kinase as a Potential Target of Treatment of Hepatocellular Carcinoma

  2019cites this paper
• Role of p53 Family Proteins in Metformin Anti-Cancer Activities

  2019cites this paper
• Thymoquinone upregulates TRAIL/TRAILR2 expression and attenuates hepatocellular carcinoma in vivo model.

  2019cites this paper
• Specific diacylglycerols generated by hepatic lipogenesis stimulate the oncogenic androgen receptor activity in male hepatocytes

  2019cites this paper
• Prevention of Lipid Peroxidation–derived Cyclic DNA Adduct and Mutation in High-Fat Diet–induced Hepatocarcinogenesis by Theaphenon E

  2018cites this paper
• Role of hepatoma‐derived growth factor in promoting de novo lipogenesis and tumorigenesis in hepatocellular carcinoma

  2018cites this paper
• Metformin as an anti-cancer agent: actions and mechanisms targeting cancer stem cells.

  2018cites this paper
• Effect of Gold Nanocomposite on the Cytotoxicity of Human Cancer Cell Lines

  2018cites this paper
• Non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, metabolic syndrome and hepatocellular carcinoma-a composite scenario.

  2018cites this paper
• The Asia–Pacific Working Party on Non‐alcoholic Fatty Liver Disease guidelines 2017—Part 2: Management and special groups

  2018cites this paper
• Anti-hyperlipidemia of garlic by reducing the level of total cholesterol and low-density lipoprotein

  2018cites this paper
• Disposition of metformin on concomitant administration of erlotinib and meloxicam in SCID mice

  2018cites this paper
• Metformin ameliorated methotrexate-induced hepatorenal toxicity in rats in addition to its antitumor activity: two birds with one stone

  2018cites this paper
• Arachidonic acid suppresses hepatic cell growth through ROS‐mediated activation of transglutaminase

  2018cites this paper
• Metformin suppresses gastric cancer progression through calmodulin‑like protein 3 secreted from tumor‑associated fibroblasts.

  2018cites this paper
• Predictive and preventive significance of AMPK activation on hepatocarcinogenesis in patients with liver cirrhosis

  2018cites this paper
• Beyond renoprotective impact; ameliorative effects of metformin on malignancies

  2018cites this paper
• Nonalcoholic fatty liver disease: current concepts, epidemiology and management strategies

  2018cites this paper
• Impact on pharmacokinetics of erlotinib by meloxicam and metformin administration in SCID mice

  2018cites this paper
• Plasma cholesterol and lipoprotein levels in relation to tumor aggressiveness and survival in HCC patients

  2018cites this paper
• De novo lipogenesis represents a therapeutic target in mutant Kras non‐small cell lung cancer

  2018cites this paper
• Oncogene-dependent addiction to carbohydrate-responsive element binding protein in hepatocellular carcinoma

  2018influential citation
• Targeted Multiplex Gene Expression Profiling to Measure High-Fat Diet and Metformin Effects on Fetal Gene Expression in a Mouse Model

  2018cites this paper
• Association between metformin and the risk of gastric cancer in patients with type 2 diabetes mellitus: a meta-analysis of cohort studies.

  2017cites this paper
• Interconnection between DNA damage, senescence, inflammation, and cancer.

  2017cites this paper
• Fatty acid synthase (FASN) as a therapeutic target in breast cancer

  2017cites this paper
• Comment to: "EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease".

  2017cites this paper
• Is Metformin a Perfect Drug? Updates in Pharmacokinetics and Pharmacodynamics.

  2017cites this paper
• Association between metformin and the risk of gastric cancer in patients with type 2 diabetes mellitus: a meta-analysis of cohort studies

  2017cites this paper
• Obesity and Hepatocellular Carcinoma

  2017cites this paper
• Hepatoprotective Effect of Curcumin on Hepatocellular Carcinoma Through Autophagic and Apoptic Pathways.

  2017cites this paper
• Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs

  2017cites this paper
• Desmoplasia suppression by metformin-mediated AMPK activation inhibits pancreatic cancer progression.

  2017cites this paper
• Metformin and Anti-Cancer Therapeutics: Hopes for a More Enhanced Armamentarium Against Human Neoplasias?

  2017cites this paper
• Silencing of solute carrier family 13 member 5 disrupts energy homeostasis and inhibits proliferation of human hepatocarcinoma cells

  2017cites this paper
• Screening Novel Molecular Targets of Metformin in Breast Cancer by Proteomic Approach

  2017cites this paper
• Metformin inhibits estrogen‐dependent endometrial cancer cell growth by activating the AMPK–FOXO1 signal pathway

  2016cites this paper
• [[The Modern View on Pathogenesis and Treatment of Nonalcoholic Fatty Liver Disease].]

  2016cites this paper
• Preventive effects of astaxanthin on diethylnitrosamine‐induced liver tumorigenesis in C57/BL/KsJ‐db/db obese mice

  2016cites this paper
• Anti-Inflammatory Effects of Metformin Irrespective of Diabetes Status

  2016cites this paper
• Effect of Garlic and Lemon Juice Mixture on Lipid Profile and Some Cardiovascular Risk Factors in People 30-60 Years Old with Moderate Hyperlipidaemia: A Randomized Clinical Trial

  2016cites this paper
• Metformin requires 4E-BPs to induce apoptosis and repress translation of Mcl-1 in hepatocellular carcinoma cells

  2016cites this paper
• EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.

  2016cites this paper
• The story of HCC in NAFLD: from epidemiology, across pathogenesis, to prevention and treatment

  2016cites this paper
• Repurposing old drugs to chemoprevention: the case of metformin.

  2016cites this paper
• A New Insight Into Metformin Action : Diabetes , Prostate Cancer , and Ion Channels

  2016cites this paper
• EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease

  2016cites this paper
• Arginine Methylation of SREBP1a via PRMT5 Promotes De Novo Lipogenesis and Tumor Growth.

  2016cites this paper
• Hepatitis B Virus ( HBV ) Core-Related Antigen During Nucleos ( t ) ide Analog Therapy Is Related to Intrahepatic HBV Replication and Development of Hepatocellular Carcinoma

  2016cites this paper
• Hepatitis B Virus (HBV) Core-Related Antigen During Nucleos(t)ide Analog Therapy Is Related to Intra-hepatic HBV Replication and Development of Hepatocellular Carcinoma.

  2016cites this paper
• A Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLD

  2016cites this paper
• EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease

  2016cites this paper
• Metformin prevents hepatocellular carcinoma development by suppressing hepatic progenitor cell activation in a rat model of cirrhosis

  2016influential citation
• Repurposing Drugs for Cancer Prevention.

  2016cites this paper
• Systematic review: Preventive and therapeutic applications of metformin in liver disease.

  2015cites this paper
• Hyaluronic acid co-functionalized gold nanoparticle complex for the targeted delivery of metformin in the treatment of liver cancer (HepG2 cells).

  2015cites this paper
• Reduction behavior induced by HL010183, a metformin derivative against the growth of cutaneous squamous cell carcinoma.

  2015cites this paper
• Mouse Models to Study Metformin Effects in Carcinogenesis

  2015cites this paper
• Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience

  2015cites this paper